Munoz-Garrido P, Fernandez-Barrena MG, Hijona E, Carracedo M, Marín JJG, Bujanda L, Banales JM. MicroRNAs in biliary diseases. World J Gastroenterol 2012; 18(43): 6189-6196 [PMID: 23180938 DOI: 10.3748/wjg.v18.i43.6189]
Corresponding Author of This Article
Jesús M Banales, PhD, Division of Hepatology and Gastroenterology, Biodonostia Research Institute-Donostia Universitary Hospital, Paseo Dr. Begiristain s/n, 20014 San Sebastián, Spain. jesus.banales@biodonostia.org
Article-Type of This Article
Guidelines For Basic Science
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Nov 21, 2012; 18(43): 6189-6196 Published online Nov 21, 2012. doi: 10.3748/wjg.v18.i43.6189
MicroRNAs in biliary diseases
Patricia Munoz-Garrido, Maite G Fernandez-Barrena, Elizabeth Hijona, Miguel Carracedo, José J G Marín, Luis Bujanda, Jesús M Banales
Patricia Munoz-Garrido, Elizabeth Hijona, Miguel Carracedo, Luis Bujanda, Jesús M Banales, Division of Hepatology and Gastroenterology, Biodonostia Research Institute, Donostia Universitary Hospital, 20014 San Sebastián, Spain
Maite G Fernandez-Barrena, Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, United States
Elizabeth Hijona, José J G Marín, Luis Bujanda, Jesús M Banales, Department of Liver and Gastrointestinal Diseases, National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, funded by the Spanish Carlos III Institute), 08036 Barcelona, Spain
José J G Marín, Department of Physiology and Pharmacology, Experimental Hepatology and Drug Targeting (HEVEFARM), Biomedical Research Institute of Salamanca (IBSAL), University of Salamanca, 37008 Salamanca, Spain
Jesús M Banales, Ikerbasque, Basque Foundation for Science, 48011 Bilbao, Spain
Author contributions: Munoz-Garrido P and Banales JM performed the manuscript concept and design, drafting of the text and critical revision; Fernandez-Barrena MG, Hijona E, Carracedo M, Marín JJG and Bufanda L performed the drafting of the manuscript and critical revision.
Correspondence to: Jesús M Banales, PhD, Division of Hepatology and Gastroenterology, Biodonostia Research Institute-Donostia Universitary Hospital, Paseo Dr. Begiristain s/n, 20014 San Sebastián, Spain. jesus.banales@biodonostia.org
Telephone: +34-943-006125 Fax: +34-943-006250
Received: May 10, 2012 Revised: July 5, 2012 Accepted: August 14, 2012 Published online: November 21, 2012
Abstract
Cholangiopathies are a group of diseases primarily or secondarily affecting bile duct cells, and result in cholangiocyte proliferation, regression, and/or transformation. Their etiopathogenesis may be associated with a broad variety of causes of different nature, which includes genetic, neoplastic, immune-associated, infectious, vascular, and drug-induced alterations, or being idiopathic. miRNAs, small non-coding endogenous RNAs that post-transcriptionally regulate gene expression, have been associated with pathophysiological processes in different organs and cell types, and are postulated as potential targets for diagnosis and therapy. In the current manuscript, knowledge regarding the role of miRNAs in the development and/or progression of cholangiopathies has been reviewed and the most relevant findings in this promising field of hepatology have been highlighted.
